Adagio Medical Holdings, Inc. (ADGM) Investor Relations Documents

Adagio Medical Holdings, Inc. (ADGM) investor relations documents from the company's IR site: 2 presentations, 38 press releases; latest deck 2026-05-01. Read in-app with summaries. First-party data.

BofA Securities 2026 Health Care Conference Presentation — Adagio Medical presentation on its vCLAS catheter for the $5.8B VT Ablation market, expecting FDA approval in Q4 2026.

Investor relations documents — source: company IR site
PublishedTypeDocument
2026-08-11Press releaseAdagio Medical Reports Second Quarter 2026 Results
2026-08-11Press releasePDF Version
2026-08-03Press releaseAdagio Medical Treats First Patient with Faster, Single-Freeze Next-Generation ULTA System
2026-05-21Press releaseAdagio Medical Submits Premarket Approval Application to FDA for vCLAS® Ventricular Ablation System for the Treatment of
2026-05-12Press releaseAdagio Medical Reports First Quarter 2026 Results and Meaningful Clinical Progress
2026-05-01PresentationBofA Securities 2026 Health Care Conference Presentation
2026-04-29Press releaseAdagio Medical to Participate in the BofA Securities 2026 Health Care Conference
2026-04-27Presentation4-27-2026 FULCRUM-VT Pivotal LBCT Investor Event Final Slides w Disclosures.pdf
2026-04-26Press releaseAdagio Medical Announces Positive Pivotal Results for vCLAS® Ventricular Ablation System
2026-04-16Press releaseAdagio Medical’s ULTA Technology to Be Featured at the Heart Rhythm 2026 Conference
2026-04-08Press releaseAdagio Medical Receives IDE Approval from the FDA to Investigate Next-Generation vCLAS® Ventricular Ablation System
2026-04-06Press releaseAdagio Medical to Participate in the 25th Annual Needham Virtual Conference
2026-04-01Press releaseAdagio Medical Ultralow Temperature Ablation U.S. Pivotal Study Results to be Presented in Late-Breaking Session at Hear
2026-03-27Press releaseAdagio Medical Reports Fourth Quarter and Full Year 2025 Results
2026-03-24Press releasePDF Version
2026-03-24Press releaseAdagio Medical Announces Publication of Pre-Clinical Results for Next Generation Ventricular Ablation Catheter
2026-03-19Press releasePDF Version
2026-03-19Press releaseAdagio Medical Highlights Recent Successful Expanded Access Cases with vCLAS™ System, Including Patients with Premature
2026-03-11Press releasePDF Version
2026-03-11Press releaseAdagio Medical to Participate in the 38th Annual Roth Conference
2026-02-20Press releasePDF Version
2026-02-04Press releasePDF Version
2026-02-04Press releaseNew Adagio Medical Publication Highlights Consistent Safety and Effectiveness with Ultralow Temperature Ablation in Broa
2026-02-02Press releasePDF Version
2026-02-02Press releaseAdagio Medical to Participate at the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conferenc
2025-11-05Press releasePDF Version
2025-11-05Press releaseAdagio Medical to Present at the Piper Sandler 37th Annual Healthcare Conference
2025-10-10Press releasePDF Version
2025-10-10Press releaseAdagio Medical Unveils Preliminary Acute Results from FULCRUM-VT U.S. Pivotal Study in Late Breaking Session at VT Sympo
2025-10-01Press releasePDF Version
2025-10-01Press releaseAdagio Medical, Inc. Announces Completion of Enrollment for FULCRUM-VT Pivotal Clinical Trial Evaluating Ultra-Low Tempe
2025-09-18Press releasePDF Version
2025-09-18Press releaseAdagio Medical FULCRUM-VT U.S. Pivotal Study Acute Results to be Presented in Late-Breaking Session at VT Symposium
2025-05-07Press releaseAdagio Medical to Present at the BofA Securities 2025 Health Care Conference
2025-04-18Press releasePDF Version
2025-04-17Press releaseAdagio Medical Holdings, Inc. Receives FDA Breakthrough Device Designation for the vCLAS(TM) Cryoablation System
2025-03-31Press releaseEarnings Release
2025-03-17Press releasePDF Version
2025-03-17Press releaseAdagio Medical Provides Clinical and Business Updates
2025-02-18Press releasePDF Version

ADGM overview · ADGM earnings · ADGM financials · ADGM KPIs · ADGM ownership · ADGM peers · ADGM filings

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.